Search clinical trials for: PD-1 inhibitor

Total 105738 results

Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease (KW-6002)

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Germany, Israel, Italy, Poland, Serbia
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Non-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Japan
Guohui Li

Recruiting

Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients

PD-1 | Immune Related Adverse Events

China
University Hospital, Montpellier

Completed

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation (ImmunEO)

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

France
Shanghai International Medical Center

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)

Advanced Solid Tumor | PD-1 Antibody | CAR-T Cells

China
Agenus Inc.

Completed

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

Advanced Solid Cancers | Advanced Solid Cancers Refractory to PD-1

United States
Ningbo Cancer Hospital

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

Advanced Malignancies | PD-1 Antibody | CAR-T Cells

China
Sun Yat-sen University

Recruiting

PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure

PD-1 Inhibitor | G-CSF

China
Shandong New Time Pharmaceutical Co., LTD

Not yet recruiting

A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NSCLC | Non-small Cell Lung Cancer | PD-1

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital... and other collaborators

Recruiting

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-003)

Radiotherapy | HNSCC | PD-1

China
Icahn School of Medicine at Mount Sinai

Recruiting

Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors

Cancer | Thyroid | PD-1

United States
Peking University

Not yet recruiting

Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ

Gastroesophageal Junction Cancer | Chemoradiotherapy | PD-1
Beijing Friendship Hospital

Not yet recruiting

PD-1 Antibody Improve Mixed Chimerism (HLH)

PD-1 Antibody | Mixed Chimerism

China
Wuhan Union Hospital, China

Recruiting

Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction

Gastroesophageal Junction Cancer | PD-1 | Neoadjuvant Chemoradiotherapy

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC (HNC-SYSU-002)

Oral Cancer | HNSCC | PD-1

China
The Affiliated Hospital of Qingdao University

Unknown

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

NSCLC Stage IV | PD-1 | ARID1A

China
Southeast University, China

Unknown

Immunoregulatory Therapy for 2019-nCoV

2019 nCoV, PD-1
RenJi Hospital

Recruiting

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

Radiotherapy | Muscle Invasive Bladder Cancer | PD-1 | HER2 Expression | Antibody-drug Conjugates

China
Xijing Hospital

Recruiting

Biomarker Analysis of Tislelizumab Combined With Chemotherapy for Perioperative Treatment of G/GEJ Adenocarcinoma

PD-1 | Locally Advanced Gastric Adenocarcinoma

China
Lei Li

Recruiting

Genetic Mutation in Recurrent Cervical Cancer

Microsatellite Instability | Recurrent Cervical Cancer | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)

Oral Cancer | PD-1

China
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern... and other collaborators

Recruiting

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Surgery | PD-1

China
Baodong Qin

Unknown

Effect of Chemotherapy on TMB in NSCLC

Chemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 Inhibitor

China
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Carcinoma, Squamous Cell, Non-small-cell Lung

Poland, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Japan, Mexico, New Zealand, Romania, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Shanghai Ninth People's Hospital Affiliated to...

Not yet recruiting

A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study

Head and Neck Cancer | Radiation | PD-1
Beijing Friendship Hospital

Not yet recruiting

PD-1 Antibody for Reactive EBV After BMT

Transplant | EBV Infection | PD-1

China
Lei Li

Recruiting

Genetic Mutation in Epithelial Ovarian Cancer

Epithelial Ovarian Cancer | Microsatellite Instability | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1

China
The First Hospital of Jilin University

Active, not recruiting

Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer (STARS-RC03)

Locally Advanced Rectal Cancer | PD-1 | Total Neoadjuvant Treatment | Tislelizumab

China
Shandong New Time Pharmaceutical Co., LTD

Not yet recruiting

A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL

RR DLBCL; PD-1; CD20
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

Hodgkin Lymphoma

United States, Brazil, Colombia, Czechia, France, Germany, Greece, Guatemala, Italy, Korea, Republic of, Mexico, Netherlands, Slovakia, South Africa, Spain, United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; National Cancer Institute (NCI)

Recruiting

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy | MSI-H Tumors

United States
Shanghai Zhongshan Hospital

Recruiting

Gut Microbiota and Cancer Immunotherapy Response

Non-Small Cell Lung Cancer

China
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Carcinoma, Non-squamous Non-small-cell Lung

Poland, Korea, Republic of, Ukraine, United States, Argentina, Australia, Austria, Canada, France, Japan, New Zealand, Romania, Russian Federation, Taiwan, Turkey, United Kingdom, Brazil, Colombia, Germany, Spain
Merck Sharp & Dohme LLC
Array BioPharma

Completed

Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)

Metastatic Colorectal Cancer

United States, Canada
Merck Sharp & Dohme LLC

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid Tumors | Hematologic Malignancies

United States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more
Merck Sharp & Dohme LLC

Completed

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Non-small Cell Lung Cancer

China, Taiwan, Japan, Korea, Republic of, United States, Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Italy, Mexico, Spain, Sweden, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Breast Cancer

Japan, Poland, United States, Australia, Belgium, Brazil, Canada, China, Colombia, Costa Rica, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Taiwan, Ukr... and more
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC

Completed

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC

Terminated

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Syndax Pharmaceuticals

Completed

An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

Melanoma

United States
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Bladder Cancer

Canada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)

Hodgkin Lymphoma
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Triple Negative Breast Neoplasms

Brazil, Canada, United States, United Kingdom, Taiwan, Australia, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Russian Federation, Singapore, Spain, Sweden, Turkey
RWJ Barnabas Health at Jersey City Medical Center

Unknown

Tumor Grade Determines PD-1/PDL-1 Expression

Ovarian Cancer | Endometrial Cancer

United States
China Medical University, China

Not yet recruiting

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

PD-1 Antibody | Gastrointestinal Tumours | DC-Cell | NK-Cell
Shanghai Zhongshan Hospital

Active, not recruiting

Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Biliary Tract Cancer | PD-1 Antibody | Lenvatinib | Gemox

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Neoplasms

Poland, United States, Australia, Canada, China, France, Greece, Israel, Japan, Korea, Republic of, South Africa, Spain

Search clinical trials for: PD-1 inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations